Product Description
Celivarone, a new noniodinated benzofuran derivative pharmacologically related to dronedarone and amiodarone, has been shown to have antiarrhythmic properties at a molecular level. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/22171925/)
Mechanisms of Action: ADRB1 Blocker, Potassium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Atrial Fibrillation|Atrial Flutter
Phase 2: Other|Atrial Fibrillation|Atrial Flutter
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2008-008412-47 |
ALPHEE | P2 |
Completed |
Unknown |
2011-05-12 |
2022-03-13 |
Treatments |
|
NCT00993382 |
ALPHEE | P2 |
Completed |
Other |
2011-05-01 |
2019-03-19 |
Treatments |
|
NCT00232310 |
CORYFEE | P2 |
Completed |
Atrial Fibrillation|Atrial Flutter |
2006-04-01 |
2019-03-21 |
Treatments |
|
NCT00233441 |
MAIA | P3 |
Completed |
Atrial Flutter|Atrial Fibrillation |
2006-05-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|